Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...

Multimodal imaging, including OCT and FAF, is crucial for differentiating between AMD and IRDs, enabling precise diagnosis.

(NAPSI)—For the nearly 40 million Americans living with diabetes, the threat to their vision unfolds quietly, often without ...

The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...

SIGLEC Phase 2b data support AVD-104 as a potential therapy to reduce GA lesion growth, preserve and improve visual acuity, and reduce conversion to neovascular AMD across all GA lesion types at 1 ...

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes. The more information amassed about geographic atrophy (GA), the better the chances of clinicians ...

NorthStar Anesthesia has continued to expand into the ophthalmology sector in 2025, partnering with a number of ophthalmology-focused ASCs. So far in 2025, the company has partnered with ASCs ...

Ella Leung, MD, a vitreoretinal surgeon at Georgia Retina, presented a study on the economic impact of anti-VEGF prior authorization requests at the 2025 annual meeting of the American Society of ...

A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers. The prior authorization ...

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ...

Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (ANNX) ...